Sectors
Share
Tariffs won't bring the manufacturing of generic pharmaceuticals back to the US, but there are alternatives
The most vulnerable US citizens are those who could feel the biggest impact from incoming pharma tariffs
Our take on why ESG in healthcare is here to stay
Trump's tariff threat on the pharmaceutical industry
By Diederik Stadig